EQUILLIUM, INC. Net Income
EQUILLIUM, INC. (EQ) reported Net Income of -$4.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-13
- EQUILLIUM, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$4.69M.
- EQUILLIUM, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$5.31M.
- EQUILLIUM, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$3.77M.
- EQUILLIUM, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$4.23M.
- EQUILLIUM, INC. net income (loss) attributable to parent for fiscal 2022 was -$62.43M.
- EQUILLIUM, INC. net income (loss) attributable to parent for fiscal 2021 was -$39.05M.
- EQUILLIUM, INC. net income (loss) attributable to parent for fiscal 2020 was -$29.81M.
- EQUILLIUM, INC. net income (loss) attributable to parent for fiscal 2019 was -$25.60M.
| Period end | Net Income (Loss) Attributable to Parent 0 month | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 7 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 10 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$4.69M 10-Q · filed 2026-08-13 | -$10.00M 10-Q · filed 2026-08-13 | -$13.78M derived: sum of 3 quarters · filed 2026-08-13 | -$18.01M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2026-03-31 | -$5.31M 10-Q · filed 2026-08-13 | -$9.09M derived: sum of 2 quarters · filed 2026-08-13 | -$13.32M derived: sum of 3 quarters · filed 2026-08-13 | -$19.05M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-12-31 | -$3.77M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-15 | -$8.01M derived: sum of 2 quarters · filed 2026-04-15 | -$13.74M derived: sum of 3 quarters · filed 2026-08-13 | -$22.40M DEF 14A · filed 2026-04-15 | ||||||
| 2025-09-30 | -$4.23M 10-Q · filed 2025-11-13 | -$9.97M derived: sum of 2 quarters · filed 2026-08-13 | -$18.62M 10-Q · filed 2025-11-13 | -$24.42M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-06-30 | -$5.74M 10-Q · filed 2026-08-13 | -$14.39M 10-Q · filed 2026-08-13 | -$20.19M derived: sum of 3 quarters · filed 2026-08-13 | -$20.19M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-03-31 | -$8.65M 10-Q · filed 2026-08-13 | -$14.45M derived: sum of 2 quarters · filed 2026-08-13 | -$14.46M derived: sum of 3 quarters · filed 2026-08-13 | -$13.99M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2024-12-31 | -$5.79M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-15 | -$5.80M derived: sum of 2 quarters · filed 2026-04-15 | -$5.33M derived: sum of 3 quarters · filed 2026-04-15 | -$8.07M DEF 14A · filed 2026-04-15 | ||||||
| 2024-09-30 | -$7.00K 10-Q · filed 2025-11-13 | $461.00K derived: sum of 2 quarters · filed 2025-11-13 | -$2.27M 10-Q · filed 2025-11-13 | -$4.62M derived: sum of 4 quarters · filed 2026-04-15 | ||||||
| 2024-06-30 | $468.00K 10-Q · filed 2025-11-13 | -$2.27M 10-Q · filed 2025-08-14 | -$4.61M derived: sum of 3 quarters · filed 2026-04-15 | -$8.32M derived: sum of 4 quarters · filed 2026-04-15 | ||||||
| 2024-03-31 | -$2.73M 10-Q · filed 2025-11-13 | -$5.08M derived: sum of 2 quarters · filed 2026-04-15 | -$8.79M derived: sum of 3 quarters · filed 2026-04-15 | -$12.13M derived: sum of 4 quarters · filed 2026-04-15 | ||||||
| 2023-12-31 | -$2.34M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-15 | -$6.05M derived: sum of 2 quarters · filed 2026-04-15 | -$9.39M derived: sum of 3 quarters · filed 2026-04-15 | -$13.34M DEF 14A · filed 2026-04-15 | ||||||
| 2023-09-30 | -$3.71M 10-Q · filed 2024-11-13 | -$7.05M derived: sum of 2 quarters · filed 2024-11-13 | -$10.99M 10-Q · filed 2024-11-13 | -$8.22M derived: sum of 4 quarters · filed 2024-11-13 | ||||||
| 2023-06-30 | -$3.34M 10-Q · filed 2024-11-13 | -$7.28M 10-Q · filed 2024-08-08 | -$4.51M derived: sum of 3 quarters · filed 2024-11-13 | -$18.16M derived: sum of 4 quarters · filed 2024-11-13 | ||||||
| 2023-03-31 | -$3.94M 10-Q · filed 2024-11-13 | -$1.17M derived: sum of 2 quarters · filed 2024-11-13 | -$14.82M derived: sum of 3 quarters · filed 2024-11-13 | -$28.95M derived: sum of 4 quarters · filed 2024-11-13 | ||||||
| 2022-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$10.88M derived: sum of 2 quarters · filed 2024-03-25 | -$25.01M derived: sum of 3 quarters · filed 2024-03-25 | -$62.43M 10-K · filed 2024-03-25 | ||||||
| 2022-09-30 | -$13.65M 10-Q · filed 2023-11-08 | -$27.78M derived: sum of 2 quarters · filed 2023-11-08 | -$65.20M 10-Q · filed 2023-11-08 | -$75.82M derived: sum of 4 quarters · filed 2023-11-08 | ||||||
| 2022-06-30 | -$14.13M 10-Q · filed 2023-11-08 | -$51.55M 10-Q · filed 2023-08-09 | -$62.17M derived: sum of 3 quarters · filed 2023-11-08 | -$72.45M derived: sum of 4 quarters · filed 2023-11-08 | ||||||
| 2022-03-31 | -$37.42M 10-Q · filed 2023-11-08 | -$48.04M derived: sum of 2 quarters · filed 2023-11-08 | -$58.32M derived: sum of 3 quarters · filed 2023-11-08 | -$67.48M derived: sum of 4 quarters · filed 2023-11-08 | ||||||
| 2021-12-31 | -$10.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$20.90M derived: sum of 2 quarters · filed 2023-03-23 | -$30.06M derived: sum of 3 quarters · filed 2023-03-23 | -$39.05M 10-K · filed 2023-03-23 | ||||||
| 2021-09-30 | -$10.28M 10-Q · filed 2022-11-14 | -$19.44M derived: sum of 2 quarters · filed 2022-11-14 | -$28.43M 10-Q · filed 2022-11-14 | -$37.35M derived: sum of 4 quarters · filed 2022-11-14 | ||||||
| 2021-06-30 | -$9.16M 10-Q · filed 2022-11-14 | -$18.15M 10-Q · filed 2022-08-15 | -$27.07M derived: sum of 3 quarters · filed 2022-11-14 | -$33.66M derived: sum of 4 quarters · filed 2022-11-14 | ||||||
| 2021-03-31 | -$8.99M 10-Q · filed 2022-11-14 | -$17.91M derived: sum of 2 quarters · filed 2022-11-14 | -$24.51M derived: sum of 3 quarters · filed 2022-11-14 | -$30.97M derived: sum of 4 quarters · filed 2022-11-14 | ||||||
| 2020-12-31 | -$8.92M 10-K · filed 2021-03-24 | -$15.52M derived: sum of 2 quarters · filed 2021-11-10 | -$21.98M derived: sum of 3 quarters · filed 2021-11-10 | -$29.81M 10-K · filed 2022-03-23 | ||||||
| 2020-09-30 | -$6.60M 10-Q · filed 2021-11-10 | -$13.06M derived: sum of 2 quarters · filed 2021-11-10 | -$20.89M 10-Q · filed 2021-11-10 | -$28.46M derived: sum of 4 quarters · filed 2021-11-10 | ||||||
| 2020-06-30 | -$6.46M 10-Q · filed 2021-11-10 | -$14.30M 10-Q · filed 2021-08-10 | -$21.86M derived: sum of 3 quarters · filed 2021-11-10 | -$27.88M derived: sum of 4 quarters · filed 2021-11-10 | ||||||
| 2020-03-31 | -$7.84M 10-Q · filed 2021-11-10 | -$15.40M derived: sum of 2 quarters · filed 2021-11-10 | -$21.42M derived: sum of 3 quarters · filed 2021-11-10 | -$27.49M derived: sum of 4 quarters · filed 2021-11-10 | ||||||
| 2019-12-31 | -$7.57M 10-K · filed 2021-03-24 | -$13.58M derived: sum of 2 quarters · filed 2021-03-24 | -$19.65M derived: sum of 3 quarters · filed 2021-03-24 | -$25.60M 10-K · filed 2021-03-24 | ||||||
| 2019-09-30 | -$6.01M 10-K · filed 2021-03-24 | -$12.08M derived: sum of 2 quarters · filed 2021-03-24 | -$18.03M 10-Q · filed 2020-11-10 | -$23.02M derived: sum of 4 quarters · filed 2021-03-24 | ||||||
| 2019-06-30 | -$6.07M 10-K · filed 2021-03-24 | -$12.02M 10-Q · filed 2020-08-12 | -$17.01M derived: sum of 3 quarters · filed 2021-03-24 | -$21.93M derived: sum of 4 quarters · filed 2021-03-24 | ||||||
| 2019-03-31 | -$5.95M 10-K · filed 2021-03-24 | -$10.94M derived: sum of 2 quarters · filed 2021-03-24 | -$15.86M derived: sum of 3 quarters · filed 2021-03-24 | -$17.62M derived: sum of 4 quarters · filed 2021-03-24 | ||||||
| 2018-12-31 | -$4.99M 10-K · filed 2020-03-26 | -$4.99M 10-K · filed 2019-03-27 | -$9.91M derived: sum of 2 quarters · filed 2020-03-26 | -$11.67M derived: sum of 3 quarters · filed 2020-03-26 | -$13.25M 10-K · filed 2020-03-26 | -$13.25M 10-K · filed 2019-03-27 | ||||
| 2018-09-30 | -$4.92M 10-K · filed 2020-03-26 | -$4.92M 10-Q · filed 2018-11-15 | -$6.68M derived: sum of 2 quarters · filed 2020-03-26 | -$8.26M 10-Q · filed 2019-11-12 | -$8.26M 10-Q · filed 2018-11-15 | -$9.37M derived: sum of 4 quarters · filed 2020-03-26 | ||||
| 2018-06-30 | -$1.76M 10-K · filed 2020-03-26 | -$1.77M 10-K · filed 2019-03-27 | -$3.34M 10-Q · filed 2019-08-12 | -$4.45M derived: sum of 3 quarters · filed 2020-03-26 | -$4.59M derived: sum of 4 quarters · filed 2020-03-26 | |||||
| 2018-03-31 | -$1.58M 10-K · filed 2020-03-26 | -$1.58M 10-K · filed 2019-03-27 | -$2.68M derived: sum of 2 quarters · filed 2020-03-26 | -$2.82M derived: sum of 3 quarters · filed 2020-03-26 | -$3.77M derived: sum of 4 quarters · filed 2020-03-26 | |||||
| 2017-12-31 | -$1.11M 10-K · filed 2019-03-27 | -$1.25M derived: sum of 2 quarters · filed 2019-03-27 | -$2.19M derived: sum of 3 quarters · filed 2019-03-27 | -$2.26M 10-K · filed 2019-03-27 | ||||||
| 2017-09-30 | -$141.03K 10-K · filed 2019-03-27 | -$1.09M derived: sum of 2 quarters · filed 2019-03-27 | -$1.16M 10-Q · filed 2018-11-15 | |||||||
| 2017-06-30 | -$947.30K 10-K · filed 2019-03-27 | |||||||||
| 2017-03-31 | -$67.19K 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |